|
1
|
Han Y, Peng Y, Fu Y, Cai C, Guo C, Liu S, Li Y, Chen Y, Shen E, Long K, et al: MLH1 deficiency induces cetuximab resistance in colon cancer via Her-2/PI3K/AKT Signaling. Adv Sci (Weinh). 7:20001122020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Samuels Y, Diaz LA Jr, Schmidt-Kittler O, Cummins JM, Delong L, Cheong I, Rago C, Huso DL, Lengauer C, Kinzler KW, et al: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7:561–573. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spandidos DA and Wilkie NM: Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature. 310:469–475. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Durrant TN and Hers I: PI3K inhibitors in thrombosis and cardiovascular disease. Clin Transl Med. 9:82020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mazloumi Gavgani F, Smith Arnesen V, Jacobsen RG, Krakstad C, Hoivik EA and Lewis AE: Class I Phosphoinositide 3-Kinase PIK3CA/p110α and PIK3CB/p110β isoforms in endometrial cancer. Int J Mol Sci. 19:39312018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blackburn PR, Milosevic D, Marek T, Folpe AL, Howe BM, Spinner RJ and Carter JM: PIK3CA mutations in lipomatosis of nerve with or without nerve territory overgrowth. Mod Pathol. 33:420–430. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murakami K, Kanto A, Sakai K, Miyagawa C, Takaya H, Nakai H, Kotani Y, Nishio K and Matsumura N: Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. Mod Pathol. doi: https://doi.org/10.1101/2021.02.25.432943. 2021. View Article : Google Scholar
|
|
8
|
Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J and DeCensi A: PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. A systematic review and meta-analysis of epidemiological studies. Clin Oncol (R Coll Radiol). 28:317–326. 2016. View Article : Google Scholar
|
|
9
|
Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V and Lianidou E: PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: A direct comparison study. Mol Oncol. 13:2515–2530. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikenoue T, Kanai F, Hikiba Y, Obata T, Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, et al: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65:4562–4567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ghodsinia AA, Lego JMT and Garcia RL: Mutation-associated phenotypic heterogeneity in novel and canonical PIK3CA helical and kinase domain mutants. Cells. 9:11162020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun B, Jiang Y, Cui H, Fang X, Han G, Dai X, Zhou S, Mao H and Wang B: Activating PIK3CA mutation promotes adipogenesis of adipose-derived stem cells in macrodactyly via up-regulation of E2F1. Cell Death Dis. 11:6002020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vasan N, Razavi P, Johnson JL, Shao H, Shah H, Antoine A, Ladewig E, Gorelick A, Lin TY, Toska E, et al: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors. Science. 366:714–723. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hong X, Zhong L, Xie Y, Zheng K, Pang J, Li Y, Yang Y, Xu X, Mi P, Cao H, et al: Matrine reverses the Warburg effect and suppresses colon cancer cell growth via negatively regulating HIF-1α. Front Pharmacol. 10:14372019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Momi N, Wali RK, Chhaparia A, Calderwood AH, Tiwari A, Ledbetter SE, DeLaCruz M and Roy HK: Su2000 PRDM16 is a novel proto-oncogene in colorectal cancer (CRC): Modulation of the early Warburg effect in field carcinogenesis. Gastroenterology. 150 (Suppl):S6062016. View Article : Google Scholar
|
|
16
|
Giuliani N, Chiu M, Bolzoni M and Bussolati O: Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage. Transl Cancer Res. 5 (Suppl 4):S885–S888. 2016. View Article : Google Scholar
|
|
17
|
Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, Jin Z, Dong B, Cao B, Feng X, et al: Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 7:119712016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng X, Hao Y and Wang Z: Targeting glutamine metabolism in PIK3CA Mutant colorectal cancers. Genes Dis. 3:241–243. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim M, Gwak J, Hwang S, Yang S and Jeong SM: Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism. Oncogene. 38:4729–4738. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, Parada LF and Karsenty G: ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 4:441–451. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Slattery ML, Lundgreen A, Herrick JS and Wolff RK: Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res. 706:13–20. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qiu Q, Jiang J, Lin L, Cheng S, Xin D, Jiang W, Shen J and Hu Z: Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways. Int J Oncol. 48:2508–2520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tserga A, Chatziandreou I, Michalopoulos NV, Patsouris E and Saetta AA: Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness. Virchows Arch. 469:35–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, et al: PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 35:2961–2970. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, et al: P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. Oncogene. 34:3968–3976. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toth K, Kuppuswamy M, Shashkova EV, Spencer JF and Wold WS: A fully replication-competent adenovirus vector with enhanced oncolytic properties. Cancer Gene Ther. 17:761–770. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yano S, Takehara K, Miwa S, Kishimoto H, Tazawa H, Urata Y, Kagawa S, Bouvet M, Fujiwara T and Hoffman RM: In vivo isolation of a Highly-aggressive variant of Triple-negative human breast cancer MDA-MB-231 using serial orthotopic transplantation. Anticancer Res. 36:3817–3820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Singleton DC and Harris AL: Targeting the ATF4 pathway in cancer therapy. Expert Opin Ther Targets. 16:1189–1202. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Juliana CA, Yang J, Cannon CE, Good AL, Haemmerle MW and Stoffers DA: A PDX1-ATF transcriptional complex governs β cell survival during stress. Mol Metab. 17:39–48. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aoki M and Fujishita T: Oncogenic roles of the PI3K/AKT/mTOR axis. Curr Top Microbiol Immunol. 407:153–189. 2017.PubMed/NCBI
|
|
31
|
Lien EC, Dibble CC and Toker A: PI3K signaling in cancer: Beyond AKT. Curr Opin Cell Biol. 45:62–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, et al: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci USA. 110:21124–21129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Salles B, Calsou P, Frit P and Muller C: The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol (Paris). 54:185–193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bartalucci N, Guglielmelli P and Vannucchi AM: Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 13 (Suppl 2):S307–S309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bao HR, Chen JL, Li F, Zeng XL and Liu XJ: Relationship between PI3K/mTOR/RhoA pathway-regulated cytoskeletal rearrangements and phagocytic capacity of macrophages. Braz J Med Biol Res. 53:e92072020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, et al: Measurement of PIP Levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell. 27:97–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
